🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

545 results for “B.” Clear

  1. Brelovitug 300 mg

    Mirum Pharmaceuticals International B.V.

    Chronic Hepatitis D Infection

    phase 3 small molecule active

    3 trials
  2. CDZ173/Leniolisib, CDZ173/Leniolisib

    Pharming Technologies B.V.

    Activated Phosphoinositide 3-Kinase Delta Syndrome

    phase 3 small molecule active

    1 trial
  3. CDZ173/Leniolisib, CDZ173/Leniolisib, CDZ173/Leniolisib

    Pharming Technologies B.V.

    Activated Phosphoinositide 3-Kinase Delta Syndrome

    phase 3 small molecule active

    1 trial
  4. CHLORURE DE POTASSIUM B. BRAUN 10 % (0,10 g/ml), solution à diluer pour perfusion, GLUCOSE 2,5 % B. BRAUN, solution pour perfusion, MINIRIN 4 microgrammes/ml, solution injectable, SODIUM LACTATE, CHLORURE DE SODIUM 0,9 % AGUETTANT, solution pour perfusion, CHLORURE DE SODIUM HYPERTONIQUE 10 % LAVOISIER, solution à diluer injectable, GLUCOSE 5 % VIAFLO, solution pour perfusion, GADOTERIC ACID

    Pari Pharma GmbH

    Severe hyponatremia and a high risk of rapid SNa overcorrection

    phase 3 small molecule active

    1 trial
  5. CHLORURE DE SODIUM 0,9 % B. BRAUN, solution injectable en ampoule, TOCILIZUMAB

    Pari Pharma GmbH

    Sickle cell disease

    phase 3 small molecule active

    1 trial
  6. COAGULATION FACTOR VIII , COAGULATION FACTOR VIIA , COAGULATION FACTOR IX , SAR439774, FACTOR VIII INHIBITOR BYPASSING ACTIVITY , ANTITHROMBIN III

    Genzyme Europe B.V.

    Hemophilia A or Hemophilia B

    phase 3 small molecule active

    1 trial
  7. CRT with triple site ventricular stimulation

    Rhythm Pharmaceuticals Netherlands B.V.

    Heart Failure

    phase 3 other completed

    1 trial
  8. Carbetocin

    Acadia Pharmaceuticals B.V.

    Hyperphagia in Prader-Willi Syndrome

    phase 3 small molecule active

    2 trials
  9. Cholic Acid

    Mirum Pharmaceuticals International B.V.

    Bile Acid Synthesis Defect

    phase 3 small molecule completed

    1 trial
  10. Cholic Acids

    Mirum Pharmaceuticals International B.V.

    Infantile Refsum's Disease

    phase 3 small molecule completed

    1 trial
  11. Cholic acid

    Mirum Pharmaceuticals International B.V.

    Inborn Errors of Bile Acid Synthesis

    phase 3 small molecule completed

    1 trial
  12. Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Zipalertinib, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Pemetrexed Fresenius Kabi 100 mg powder for concentrate for solution for infusion

    Taiho Pharma Netherlands B.V.

    Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations

    phase 3 small molecule active

    1 trial
  13. Class I or III Antiarrhythmic Medications

    Rhythm Pharmaceuticals Netherlands B.V.

    Atrial Fibrillation

    phase 3 small molecule completed

    1 trial
  14. Coronary artery bypass grafting

    Rhythm Pharmaceuticals Netherlands B.V.

    Ischemic Heart Failure

    phase 3 other completed

    1 trial
  15. DTG + 3TC

    ViiV Healthcare B.V.

    HIV Infections

    phase 3 small molecule completed

    1 trial
  16. DUOFAG, Chlorid sodný B. Braun 0,9 % infuzní roztok

    Lacuna Pharma Pty Ltd

    Complicated skin wounds (wounds healing per secundam via granulation tissue) - either as a complication of healing of acute wounds (infected surgical or traumatic wounds) or chronic wounds, in both cases infected with S. aureus and/or P. aeruginosa.

    phase 3 small molecule active

    1 trial
  17. Dolutegravir/abacavir/lamivudine FDC

    ViiV Healthcare B.V.

    Infection, Human Immunodeficiency Virus

    phase 3 small molecule completed

    1 trial
  18. Double-blind 200 mg imsidolimab

    Vanda Pharmaceuticals Netherlands B.V.

    Generalized Pustular Psoriasis

    phase 3 small molecule terminated

    1 trial
  19. Elenestinib

    Blueprint Medicines (Netherlands) B.V.

    Indolent Systemic Mastocytosis

    phase 3 small molecule active

    1 trial
  20. Eliglustat, Cerezyme 400 Units Powder for concentrate for solution for infusion, Cerezyme 400 Units Powder for concentrate for solution for infusion, Eliglustat, Eliglustat, Cerezyme 400 Units Powder for concentrate for solution for infusion, Eliglustat

    Genzyme Europe B.V.

    Gaucher's disease type I; Gaucher's disease type III

    phase 3 small molecule active

    1 trial
  21. Everolimus-ratiopharm® 2,5 mg Tabletten, GOSERELIN , ORSERDU 86 mg film-coated tablets, ORSERDU 345 mg film-coated tablets, LEUPRORELIN , DEXAMETHASONE , The investigational product is as follows: white tablets, elongated, flat, rounded edges, about 10 mm long and 4 mm wide, with the embossing "EV" on one side and "2.5" on the other side. The list of excipients of Placebo tablet is as follows: Lactose monohydrate, Polyplasdone, Cellulose microcrystalline, Magnesium stearate, Hypromellose., TRIPTORELIN

    Stemline Therapeutics B.V.

    patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative, ESR1-mutated, advanced breast cancer progressing to endocrine therapy and CDK4/6 inhibitors.

    phase 3 small molecule active

    1 trial
  22. Flecainide or Sotalol or Propafenone

    Rhythm Pharmaceuticals Netherlands B.V.

    Paroxysmal Atrial Fibrillation

    phase 3 small molecule completed

    1 trial
  23. Futibatinib, FULVESTRANT

    Taiho Pharma Netherlands B.V.

    Malignant Solid Tumors

    phase 3 small molecule active

    1 trial
  24. Givosiran

    Alnylam Netherlands B.V.

    Acute Hepatic Porphyria

    phase 3 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources